Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 70HER2-positive Breast Cancer 15Carcinoma, Non-Small-Cell Lung 6HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4HER2 Positive Breast Cancer 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Solid Tumor 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non-squamous NSCLC 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1

Interventions

pyrotinib 2Surgical Procedures, Operative 2pertuzumab 1Trastuzumab 1Neoadjuvant Therapy 1Mastectomy 1Leuprolide 1Goserelin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Cancer Invasive × pyrotinib × Clear all
NCT05910398 2025-11-18

CORINNE-PI

RenJi Hospital

Phase 3 Recruiting
488 enrolled
Breast

Breast Cancer Invasive

NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡